Cost-Effectiveness of Partner Pharmacotherapy in Screening Women for Asymptomatic Infection with Chlamydia Trachomatis
- 1 May 2001
- journal article
- Published by Elsevier in Value in Health
- Vol. 4 (3) , 266-275
- https://doi.org/10.1046/j.1524-4733.2001.43009.x
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Health and Cost-Benefits of Chlamydia Screening in Young WomenSexually Transmitted Diseases, 1999
- Chlamydia trachomatis in Adolescents and AdultsPharmacoEconomics, 1998
- Performance and Cost-Effectiveness of Selective Screening Criteria for Chlamydia trachomatis Infection in WomenSexually Transmitted Diseases, 1997
- Prevention of Pelvic Inflammatory Disease by Screening for Cervical Chlamydial InfectionNew England Journal of Medicine, 1996
- A Cost-effectiveness Analysis of Screening and Treatment for Chlamydia trachomatis Infection in Asymptomatic WomenAnnals of Internal Medicine, 1996
- New Opportunities for Chlamydia PreventionSexually Transmitted Diseases, 1995
- An Economic Evaluation of Screening for Chlamydia trachomatis in Adolescent MalesPublished by American Medical Association (AMA) ,1993
- Toward Control of Sexually Transmitted Chlamydial InfectionsAnnals of Internal Medicine, 1993
- Screening for Chlamydia trachomatis in adolescent males: a cost-based decision analysis.American Journal of Public Health, 1990
- Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countriesAmerican Journal of Obstetrics and Gynecology, 1980